1. Investigate the rationale behind the new nomenclature and definition of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH).

2. Examine the most current practice guidance for the management of MASLD/MASH.

3. Illustrate the role of the pharmacist in improving access to care for patients with MASLD/MASH.

4. Differentiate the non-invasive tests and biomarkers for diagnosis and long-term disease state monitoring in patients with MASLD/MASH.

5. Identify the role of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, and other newer pharmacologic agents for the treatment of MASLD/MASH.

1. Examine recent guideline updates and clinical pearls in the care of pregnant populations.

2. Analyze new drug approvals for use in the care of pregnant populations.

3. Examine recent guideline updates and clinical pearls in the care of pediatric populations.

4. Analyze new drug approvals for use in the care of pediatric populations.

5. Examine recent guideline updates and clinical pearls in the areas of CART cell therapy, bispecific antibodies, and immunotherapy.

6. Analyze clinical pearls related to the management of CAR-T cell/immunotherapy-related toxicities.

7. Examine recent guideline updates and clinical pearls in the care of solid organ transplant recipients.

8. Analyze new drug approvals for use in the care of solid organ transplant recipients.

1. Summarize the key updates in the 2025 KDIGO anemia guidelines.

2. Analyze the latest evidence supporting revised recommendations for anemia management in CKD, including iron therapy and erythropoiesis-stimulating agents (ESAs).

3. Discuss the clinical implications of the 2025 KDIGO guideline changes, particularly in iron supplementation and ESA use in CKD.

4. Evaluate strategies for integrating new recommendations, including HIF-PHIs and other therapies, into nephrology practice for optimized patient outcomes and monitoring techniques.

1. Review an in-depth update on pre-departure vaccine needs and clinical pearls (focus on yellow fever, typhoid, hepatitis A and B).

2. Discuss strategies for expanding vaccination services to meet the needs of diverse patient populations.

3. Describe successful models that incorporate pharmacists into travel health services and global healthcare initiatives.

4. Discuss collaborative practice agreements, pre-travel consultations, and post-travel follow-ups that pharmacists can manage.

5. Identify strategies for pharmacists to engage in collaborative practices in international healthcare missions.

6. Recognize how pharmacists can contribute to vaccine accessibility and education for immigrant/migrant populations and global health initiatives.

1. Review updated recommendations regarding antithrombotic medications per the 2023 AGS Beers Criteria®.

2. Identify antithrombotic medications that are potentially inappropriate for older adults.

3. Identify risk factors for bleeding and thrombosis in an older adult patient.

4. Outline safe and effective antithrombotic medication use among older adults.

5. Recognize situations where an older adult patient may no longer benefit from antithrombotic therapy.

6. Describe strategies for appropriate deprescribing of antithrombotic agents.

1. Identify non-government grant sources relevant to clinical pharmacy research. 

2. Review the priorities of non-government funding sources.

3. Locate non-government source grant funding.

4. Define key components of a successful grant application.

1. Describe the clinical consequences of disproportionate free valproate concentrations.

1. Outline antiretroviral therapies available for PrEP, PEP and treatment (long-acting injectables).

2. Recognize common implementation barriers to care for people living with HIV (PLWH).  

3. Discuss strategies to overcome common implementation barriers to care for PLWH. 

4. Describe community-based processes promoting billing and sustainability. 

1. Review diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD).

2. Discuss the mechanism of action of different stimulant medications in the treatment of ADHD in pediatric and adult patients.

3. Identify alternative ADHD medication options in the setting of a medication shortage and various patient populations.

4. Review the mechanism of action for monoclonal antibody therapy in Alzheimer’s Disease.

5. Discuss the risks and benefits of monoclonal antibody use in Alzheimer’s Disease.

6. Identify ideal candidates for monoclonal antibody therapy in people with Alzheimer’s Disease.

1. Describe cornerstone medication classes used in treatment of heart failure secondary to congenital heart disease.

2. Outline the role of novel agents (SGLT2 inhibitors and ARNI therapy) for treatment of pediatric heart failure secondary to congenital heart disease.

3. Explain the criteria for pediatric patients who would qualify for the implantation of ventricular assist devices (VADs).

4. Summarize anticoagulation considerations in pediatric patients with VADs who are awaiting heart transplant.

5. Discuss differences in outcomes when comparing heart failure in patients with and without underlying congenital heart disease.

6. Identify primary recommendations for the pediatric pharmacist managing adult congenital heart disease heart failure (ACHD-HF) exacerbations in the pediatric intensive care unit setting.

1. Evaluate data regarding infection risk with parenteral nutrition.

2. Compare lipid injectable emulsion products for use in parenteral nutrition.

3. Formulate a nutrition plan utilizing ASPEN and ESPEN critical care nutrition support guidelines.

4. Create pathways for safe transitions of care for patients receiving parenteral nutrition.

5. Identify adverse effects that can occur as a result of nutrition support product shortages.

6. Develop best practices for managing parenteral nutrition-related drug shortages.

1. Discuss the mechanisms of action of newer incretin- and peptide-based therapies developed for the management of persons with overweight or obesity.

2. Review evidence supporting the use of newer incretin-based and peptide therapies in the management of persons with overweight or obesity.

3. Describe recent updates in clinical practice guidelines for the management of persons with overweight or obesity.

4. Identify changes to policies related to the coverage of pharmacotherapy for weight management and its impact on medication access.

5. Explain the impact of new evidence, practice recommendations, and policy updates to the management of overweight and obesity through a patient case.

1. List emerging organisms that are becoming more commonly encountered in the setting of climate change.

2. Select appropriate management strategies and antimicrobial therapy when available or appropriate for tick-borne and zoonotic diseases.

3. Describe the impact of drug shortages and supply chain disruptions on provision of optimized antimicrobial therapy and infection diagnosis.

4. Review potential mitigation strategies to respond to drug shortages and supply chain disruptions affecting infection management and stewardship efforts.

5. Discuss the expanding role of artificial intelligence (AI) in antimicrobial stewardship.

6. Identify stewardship interventions where participation from staff pharmacists, nurses, and other healthcare personnel can be incorporated.

1. Outline the paradigm shift in the treatment of patients with solid tumors toward cellular therapy.

2. Discuss key literature leading to the approval of novel, cellular therapies for the treatment of solid tumors.

3. Review toxicity profiles of cellular therapies used in solid tumor versus hematologic malignancies.

4. Explore strategies to mitigate toxicities associated with cellular therapies.

5. Review monitoring and treatment plan for a patient with a solid tumor receiving a novel cellular therapy.

1. Summarize recent literature findings expected to be clinically impactful to oncology pharmacy practice.

2. Summarize recent literature findings expected to be clinically impactful to rheumatology pharmacy practice.

3. Summarize recent literature findings expected to be clinically impactful to neurology pharmacy practice.

4. Summarize recent literature findings expected to be clinically impactful to antithrombotic therapy pharmacy practice.

5. Describe the implications of recent literature findings on pharmacy practice in the areas of oncology, rheumatology, neurology, or antithrombotic therapy.

1. Select an optimal induction and paralytic agent for a patient using evidence-based guideline recommendations and recent literature.  

2. Develop a pharmacotherapy plan to prevent and/or treat peri-intubation hypotension. 

3. Given a patient case, choose the most appropriate paralytic reversal strategy.

1. Compare mechanism and indications between immune checkpoint inhibitor and immune effector cell therapies.

2. Recognize presentation of immune checkpoint inhibitor-related toxicity in commonly involved organ systems.

3. Design a therapeutic monitoring plan for immune checkpoint inhibitor therapy.

4. Differentiate the presentation of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

5. Formulate a management strategy for toxicity related to immune effector cell therapy.

1. Explore the impact of social determinants of health on the optimal use of healthcare device technologies.

2. Examine the benefits, limitations, and best practices for the use of smart inhalers and other adherence monitoring systems.

3. Assess the benefits, limitations, and best practices for the use of implantable cardiac monitoring and other remote physiologic monitoring devices.

4. Evaluate the benefits, limitations, and best practices for the use of technology in the management of diabetes.

5. Illustrate the role of the pharmacist in accessing and implementing healthcare device technologies in patient care.

1. Recognize the signs and symptoms of drug-induced hyperthermia and its associated risk factors.

2. Define the pharmacist’s role in drug-induced hyperthermia management and prevention.

3. Develop streamlined processes for the identification and continued treatment of drug-induced hyperthermia in clinical settings.

4. Describe the role of a drug-induced hyperthermia response team.

6. Describe the advantages and limitations of using AI in qualitative research.

1. Evaluate current literature regarding agents used for sedation and analgesia in the setting of procedural sedation.

2. Discuss patient-specific variables that have the potential to impact the safety and efficacy of the various pharmacotherapy options used in procedural sedation.

3. Critique procedural sedation pharmacotherapy implementation strategies with the goal of optimizing pharmacokinetic and pharmacodynamic principles.

4. Recognize options for alternative routes of administration and potential considerations based on patient-specific factors.

5. Identify important components that should be included in workflows and protocols for procedural sedation (e.g., stocking atomizers for intranasal administration, antidotal therapy availability, bedside monitoring).

2. Apply universal screening techniques for substance use disorders.

4. Develop a patient-centered and evidence-based harm reduction and treatment plan for opioid use disorder

1. Describe the pharmacist’s role in transitioning a patient to and from dialysis.

2. Outline a transition plan for the dialysis patient transitioning to transplant and the transplant patient transitioning to dialysis.

3. Discuss the pharmacist’s role in age-based transition of a pediatric transplant recipient.

4. Outline a transition plan for the transplant patient from pediatric to adult care. 

5. Describe the importance of accurate reconciliation in solid organ transplant recipients.

6. Define the role of the pharmacist in the transition of transplant recipients between healthcare settings.

1. Describe prevalent myths in the treatment and management of infectious diseases in adult and pediatric patients.

2. Practice effective antimicrobial stewardship within individual and institutional practice.

3. Recommend optimal antibiotic use to prevent resistance and improve outcomes.

1. Explain the impact of AI and retracted studies in diverse practice settings including formulary management and medical writing.

2. Identify the role of AI in helping learners and clinicians identify and manage retracted studies and resource access across diverse practice settings.

3. Discuss the impact of AI in drug information operations, including medication safety and decision-making processes.

4. Describe updates in direct-to-consumer advertising (DTCA) regulations, and its impact on drug information communications by learners and clinicians.

5. Identify how advertising misinformation may spread through influencers on social media, impacting consumers.

6. Describe how AI aids in identifying resource access and allocation, particularly in underserved low-income settings.

1. Describe the evolution of kidney function estimation equations including rationale for the development of non-race-based estimated glomerular filtration rate (eGFR) equations. 

2. Interpret the rationale, recommendations, and supporting evidence for using non-race-based eGFR equations rather than eCrCl (Cockcroft-Gault (C-G) equation) for drug-related decisions.

3. Examine various methods for estimating eGFR for drug-related decision-making.

4. Select the most appropriate eGFR equation for drug dosing depending on the clinical scenario. 

5. Formulate a plan to best implement the change from the Cockcroft-Gault (C-G) eCrCl equation to the CKD-EPI eGFR equations for drug dosing within your pharmacy practice.

1. Assess recent trends in SGLT2i use for hospitalized patients.

2. Analyze the evidence for continuing or initiating SGLT2i in hospitalized patients without diabetes.

3. Interpret signs, symptoms, and laboratory values to recognize SGLT2i adverse events.

4. Evaluate the risks versus benefits of SGLT2i use in hospitalized patients.

5. Examine trends in use of GLP1-RAs in patients without diabetes.

6. Recommend when to continue or hold GLP1-RA and whether re-titration is required.

1. Summarize updated treatment pathways for lipid management according to the most recent guidelines.

2. Differentiate recommendations for targeting low-density lipoprotein cholesterol (LDL-C) levels for patients at risk for cardiovascular events.

3. Evaluate the role of newer non-statin agents in lipid management.

4. Debate the optimal approach to cardiovascular risk reduction using lipid-lowering therapy.

1. Define hyperglycemia in the perioperative period.

2. Differentiate between treatment strategies to address glycemic management in the perioperative period.

3. Demonstrate the use of glycemic management devices, such as continuous glucose monitors and insulin pumps, within the perioperative period.

4. Practice implementing  management strategies for glycemic device management.

5. Apply evidence-based practices to antihyperglycemic agents in the perioperative period to enhance patient safety. 

1. Describe physiological changes in lung function during pregnancy and their clinical implications.

2. Outline evidence-based strategies for managing respiratory conditions while ensuring maternal-fetal safety.

3. Select safe medication management plans for chronic pulmonary conditions in persons with childbearing potential, incorporating appropriate monitoring parameters and risk mitigation strategies.

4. Summarize appropriate contraception counseling for patients with high-risk pulmonary conditions.

5. Review pulmonary embolism risk factors and evidence-based prevention strategies for pregnant patients with respiratory conditions.

6. Discuss patient-centered care plans that address health disparities in maternal health outcomes.

1. Review updates in treatment of GEJ, gastric and colorectal cancers. 

2. Discuss targetable biomarkers within GI malignancies. 

3. Review primary literature for targeted agents recently FDA approved for GI malignancies. 

4. Implement toxicity management strategies for targeted agents recently FDA approved for management of GI malignancies. 

5. Identify appropriate treatments for patients with GI malignancies through patient cases.